Population pharmacokinetics of brexpiprazole in Japanese healthy subjects and patients with schizophrenia
- 11 February 2025
- journal article
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 62, 101057
Abstract
No abstract availableKeywords
All Related Versions
This publication has 20 references indexed in Scilit:
- Population Pharmacokinetic Analysis of Brexpiprazole to Support its Indication and Dose Selection in Adolescents With SchizophreniaThe Journal of Clinical Pharmacology, 2023
- Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019Molecular Psychiatry, 2023
- An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participantsEuropean Journal of Clinical Pharmacology, 2020
- Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017Epidemiology and Psychiatric Sciences, 2020
- Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016Schizophrenia Bulletin, 2018
- Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With SchizophreniaThe Journal of Clinical Pharmacology, 2017
- SchizophreniaThe Lancet, 2016
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophreniaSchizophrenia Research, 2015
- A reduction in between subject variability is not mandatory for selecting a new covariateJournal of Pharmacokinetics and Pharmacodynamics, 2012
- Dopamine D2 Receptor Occupancy and Clinical EffectsJournal of Clinical Psychopharmacology, 2011